Search results for "Cancer survivors"

showing 10 items of 58 documents

Evaluación y rehabilitación neuropsicológica en oncología pediátrica.

2003

Objetivo. El presente trabajo tiene como objetivo el estudio de los efectos neuropsicológicos a largo plazo del cáncer infantil y sus tratamientos así como plantear propuestas para la rehabilitación cognitiva. Método. El método ha consistido en una revisión sistemática de los resultados en la literatura científica acerca de los efectos de la quimioterapia y la radioterapia sobre el SNC y en las funciones cognitivas y conductuales detectados a través de estudios de neuroimagen como calcificaciones y cambios en la sustancia blanca. Presentamos, además, el protocolo de evaluación neuropsicológica ejemplificado con un diagnóstico frecuente que presenta deterioro generalizado. Proponemos un prog…

Càncer en els infantslcsh:PsychologyNeuropsychologyCranial irradiationLate effectslcsh:BF1-990RehabilitationPediatric cancer survivorslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282
researchProduct

Predicting physical activity change in cancer survivors: an application of the Health Action Process Approach

2021

HealthAction planning; Behavior change; Cancer survivors; Exercise; Theory; OncologyCancer
researchProduct

Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer

2021

Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at a…

InfertilityAdultMalemedicine.medical_specialtyAdolescentfertility preservationmedia_common.quotation_subjectMEDLINEMedizinFertilityGuidelines as Topic03 medical and health sciences0302 clinical medicineCancer SurvivorsSDG 3 - Good Health and Well-beingNeoplasmsMedicineHumansgonadotoxic therapiesFertility preservationYoung adultGrading (education)Childmedia_commonchildhoodCancer030219 obstetrics & reproductive medicinebusiness.industryCancerGuidelinemedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicineDisease Progressionyoung adultFemalebusinessinfertilityreproductive medicineThe Lancet Oncology
researchProduct

[Fertility preservation in the oncology patient].

2017

In recent years, medical advances have substantially improved survival of cancer patients, generating growing concern about the quality of life of the survivors. Increased attention has been paid to reproductive problems after oncological treatments. International guidelines on fertility preservation in cancer patients require that healthcare teams discuss, as early as possible, the impact of cancer treatments on fertility and encourage access to fertility preservation techniques. The development of these techniques in women is a recent effort and many patients and health care providers are not familiar with their rapid expansion. This article discusses indications, results, and risks of th…

Infertilitymedicine.medical_specialtyInternationalitymedia_common.quotation_subjectlcsh:MedicineImproved survivalFertility03 medical and health sciences0302 clinical medicineCancer SurvivorsNeoplasmsHealth caremedicineHumansFertility preservationIntensive care medicinemedia_commonlcsh:R5-920030219 obstetrics & reproductive medicinebusiness.industryRapid expansionlcsh:RCancerFertility PreservationGeneral Medicinemedicine.diseasefemaleFertility030220 oncology & carcinogenesisPractice Guidelines as TopicQuality of Lifeinfertilitylcsh:Medicine (General)businessMedwave
researchProduct

Long-term health-related quality of life of breast cancer survivors remains impaired compared to the age-matched general population especially in you…

2021

Objective To investigate long-term health-related quality of life (HRQoL) changes over time in younger compared to older disease-free breast cancer survivors who participated in a prospective randomized exercise trial. Methods Survivors (aged 35–68 years) were randomized to a 12-month exercise trial after adjuvant treatment and followed up for ten years. HRQoL was assessed with the generic 15D instrument during follow-up and the younger (baseline age ≤ 50) and older (age >50) survivors’ HRQoL was compared to that of the age-matched general female population (n = 892). The analysis included 342 survivors. Results The decline of HRQoL compared to the population was steeper and recovery slower…

MENOPAUSESYMPTOMSIMPACTCancer survivorsHealth-related quality of life3122 CancersBreast NeoplasmselämänlaatuFollow-up studiestoipuminenUtilitySurveys and Questionnairesbreast neoplasmscancer survivorsHumansProspective StudiesSurvivorsExerciseRC254-282exerciserintasyöpäkuntoliikuntaNeoplasms. Tumors. Oncology. Including cancer and carcinogensfollow-up studieshumanitieshealth-related quality of lifeutilityQuality of LifesyöpätauditFemaleOriginal ArticleseurantatutkimusPHYSICAL PERFORMANCEliikuntahoitoBreast (Edinburgh, Scotland)
researchProduct

Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of th…

2021

Abstract Background Current knowledge about the promotion of long-term physical activity (PA) maintenance in cancer survivors is limited. The aims of this study were to 1) determine the effect of self-regulatory BCTs on long-term PA maintenance, and 2) identify predictors of long-term PA maintenance in cancer survivors 12 months after participating in a six-month exercise intervention during cancer treatment. Methods In a multicentre study with a 2 × 2 factorial design, the Phys-Can RCT, 577 participants with curable breast, colorectal or prostate cancer and starting their cancer treatment, were randomized to high intensity exercise with or without self-regulatory behaviour change technique…

MaleCancer ResearchTime FactorsCancer survivorsLogistic regressionBody Mass Indexlaw.inventionTobacco UseProstate cancerRandomized controlled trialBehavior TherapylawOdds RatioMedicineRC254-282DeterminantsHigh intensityNeoplasms. Tumors. Oncology. Including cancer and carcinogensBehaviour changeMiddle AgedBehavioural supportEndurance TrainingVDP::Medisinske Fag: 700::Helsefag: 800OncologySelf-regulationRegression AnalysisFemaleColorectal NeoplasmsMonth follow upmedicine.medical_specialtyBehaviour changeMaintenancePhysical activityBreast NeoplasmsSelf-ControlConfidence IntervalsGeneticsHumansExerciseSwedenMotivationCancer och onkologibusiness.industryResearchProstatic NeoplasmsCancerResistance Trainingmedicine.diseaseActigraphyCancer and OncologyQuality of LifePhysical therapybusinessFollow-Up StudiesBMC Cancer
researchProduct

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct

PanCareLIFE

2018

Aims: Survival after cancer diagnosed during childhood or adolescence continues to improve with new treatments and supportive therapies. Optimal long-term care requires that risks to vulnerable organs are clearly defined and translated into guidelines that are implemented into practice. PanCareLIFE is a pan-European consortium that addresses survivorship issues comprising fertility, hearing impairment and quality of life. This article describes the scientific basis of PanCareLIFE's studies.Methods: PanCareLIFE involves 17 partner institutions from eight European countries, with additional 11 data providers from five other countries. Study designs and methods include molecular genetic, cohor…

MaleGerontologyCancer ResearchLongitudinal studyMedizinPilot ProjectsChildhood cancer survivors0302 clinical medicineNeoplasmsLYMPHOMAMedicineFertility preservationChild610 Medicine & healthEARLY MENOPAUSEOVARIAN-FUNCTIONmedia_commonSURVIVORSOUTCOMES030219 obstetrics & reproductive medicineFertility PreservationGENETIC-VARIATIONCHEMOTHERAPYEuropeOncologyChild Preschool030220 oncology & carcinogenesisCohortFemalemedicine.symptom360 Social problems & social servicesAdultQuality of lifeAdolescentHearing lossmedia_common.quotation_subjectFertilityGuidelinesYoung Adult03 medical and health sciencesQuality of life (healthcare)SDG 3 - Good Health and Well-beingHumansCHILDHOOD-CANCERbusiness.industryClinical study designLate effectsHEARING-LOSSInfant NewbornInfantOtotoxicityLong-Term CareGonadal impairmentLong-term careFeasibility StudiesbusinessFOLLOW-UPEuropean Journal of Cancer
researchProduct

Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998–2012

2021

Abstract Background The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods We analyzed two population‐based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population‐based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC i…

MaleOncologyCancer Researchmedicine.medical_specialtypopulation-based cancer registriesPopulationSocio-culturaleSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyCohort StudiesRisk FactorsProstateInternal medicinepopulation‐based cancer registriesmedicinethyroid cancerHumanscancer survivorsRadiology Nuclear Medicine and imagingRegistriesThyroid NeoplasmsOverdiagnosiseducationThyroid cancerResearch ArticlesRC254-282cancer survivors; Italy; population-based cancer registries; relative risk; second primary cancer; thyroid cancereducation.field_of_studycancer survivors Italy population-based cancer registries relative risk second primary cancer thyroid cancerbusiness.industryIncidenceIncidence (epidemiology)ThyroidNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerNeoplasms Second PrimaryHistory 20th Centurymedicine.diseaserelative riskmedicine.anatomical_structureOncologyItalyRelative riskFemalesecond primary cancerbusinessCancer PreventionResearch Article
researchProduct

Coagulation and inflammation in long‐term cancer survivors: results from the adult population

2018

Essentials The increase of cancer survival remains curtailed by cardiovascular mortality. We studied a large range of inflammatory and coagulation biomarkers in long-term cancer survivors. Cancer history has an important impact on mortality independent of cardiovascular risk factors. Fibrinogen and von Willebrand factor are potential biomarkers in survivors of increased mortality. Summary Background The advances in cancer treatment and detection of early cancer have resulted in a steady increase in the number of of cancer survivors over the years. However, because of the long-term toxic effects of chemotherapy and radiotherapy, the incidence of cardiovascular disease (CVD) is increasing in …

MaleOncologyTime Factorsmedicine.medical_treatmentDiseasecoagulation factors030204 cardiovascular system & hematologyFibrinogen0302 clinical medicineCancer Survivorscardiovascular diseaseRisk FactorsGermanyProspective StudiesRISKIncidence (epidemiology)survivorsHematologyMiddle AgedPrognosisCARDIOVASCULAR-DISEASECardiovascular Diseases030220 oncology & carcinogenesisCohortFemaleHEALTHInflammation Mediatorsmedicine.drugAdultmedicine.medical_specialtyVON-WILLEBRAND-FACTORRisk AssessmentOVARIAN-CANCER03 medical and health sciencesInternal medicinevon Willebrand FactormedicinecancerHumansCOHORTBlood CoagulationMETAANALYSISAgedInflammationProportional hazards modelbusiness.industryMORTALITYFibrinogenCancermedicine.diseaseRadiation therapyATHEROSCLEROSISPLASMA-FIBRINOGENOvarian cancerbusinessBiomarkersJournal of Thrombosis and Haemostasis
researchProduct